Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan
Hydrochlorothiazide
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
Patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. All patients must give a separate written informed consent for participation in the open-label follow-up.
- Mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmHg measured by manual cuff sphygmomanometer
- Mean seated systolic blood pressure ≥ 140 mmHg, measured my manual cuff
- A 24-hour mean diastolic blood pressure, measured by ABPM (ambulatory blood pressure measurement), of ≥ 85 mmHg
- Age 18 or older
- Patient's written informed consent in accordance with GCP (Good Clinical Practice) and local legislation
Exclusion Criteria:
- Patients with a clinically significant change in ECG from baseline that was reported as an adverse event during the preceding clinical trial
- Patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
- Patients who discontinued the preceding telmisartan clinical trial due to an adverse event
- Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Telmisartan
Arm Description
Outcomes
Primary Outcome Measures
Achievement of goal blood pressure response defined by a mean sitting diastolic blood pressure <90 mmHg
Need for addition of hydrochlorothiazide or subsequent change in antihypertensive therapy
Time to addition of hydrochlorothiazide or any subsequent change in antihypertensive therapy
Mean sitting diastolic blood pressure during each visit
Mean sitting systolic blood pressure during each visit
Number of patient with adverse events
Changes from baseline in heart rate
Number of patients with abnormal changes in 12-Lead ECG (electrocardiogram)
Number of patients with abnormal changes in laboratory parameters
Number of patients with abnormal findings in physical examination
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02177422
Brief Title
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
Official Title
Open-Label Follow-up Trial on Efficacy and Safety of Chronic Administration of Telmisartan 80 mg (Micardis®) Tablets as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
June 1998 (undefined)
Primary Completion Date
November 1999 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The primary objective of this trial was to assess the efficacy and safety of telmisartan 80 mg during open-label, long-term treatment. An additional objective was to assess the efficacy and safety of concomitant administration of telmisartan 80 mg and HCTZ (Hydrochlorothiazide) and/or any other therapies commonly used in the treatment of hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Enrollment
489 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Telmisartan
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Description
telmisartan 80 mg once daily
Intervention Type
Drug
Intervention Name(s)
Hydrochlorothiazide
Intervention Description
12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
Primary Outcome Measure Information:
Title
Achievement of goal blood pressure response defined by a mean sitting diastolic blood pressure <90 mmHg
Time Frame
Up to one year
Title
Need for addition of hydrochlorothiazide or subsequent change in antihypertensive therapy
Time Frame
Up to one year
Title
Time to addition of hydrochlorothiazide or any subsequent change in antihypertensive therapy
Time Frame
Up to one year
Title
Mean sitting diastolic blood pressure during each visit
Time Frame
At months 3, 6, 9, 12
Title
Mean sitting systolic blood pressure during each visit
Time Frame
At months 3, 6, 9, 12
Title
Number of patient with adverse events
Time Frame
Up to one year
Title
Changes from baseline in heart rate
Time Frame
Baseline and at months 3, 6, 9, 12
Title
Number of patients with abnormal changes in 12-Lead ECG (electrocardiogram)
Time Frame
Baseline and 12 months
Title
Number of patients with abnormal changes in laboratory parameters
Time Frame
Baseline and 12 months
Title
Number of patients with abnormal findings in physical examination
Time Frame
Baseline and at 12 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. All patients must give a separate written informed consent for participation in the open-label follow-up.
Mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmHg measured by manual cuff sphygmomanometer
Mean seated systolic blood pressure ≥ 140 mmHg, measured my manual cuff
A 24-hour mean diastolic blood pressure, measured by ABPM (ambulatory blood pressure measurement), of ≥ 85 mmHg
Age 18 or older
Patient's written informed consent in accordance with GCP (Good Clinical Practice) and local legislation
Exclusion Criteria:
Patients with a clinically significant change in ECG from baseline that was reported as an adverse event during the preceding clinical trial
Patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
Patients who discontinued the preceding telmisartan clinical trial due to an adverse event
Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.260_U00-1706.pdf
Description
Related Info
Learn more about this trial
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
We'll reach out to this number within 24 hrs